Evidence map›Paper›PMID 41420205›Full record

ArticleBMC microbiology2025

A novel one-tube nested fluorescence melting curve analysis for rapid detection of drug-resistant Mycobacterium tuberculosis.

Yingchao Chang, Gaowen Liu, Xiaofei Li, Mi Zhang, Tingting Diao, Cuixian Yang, Xinlin Wu, Yungui Tu, Hongji Zhang, Chao Zhou and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Heteroresistance inFrontiers in cellular and infection microbiology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yingchao Chang *Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China.
Gaowen Liu *Yunnan Kecan Biotechnology Co., Ltd, Kunming, China.
Xiaofei LiDepartment of Clinical Laboratory, The Third People's Hospital of Kunming City, Kunming, China.
Mi ZhangMedical Laboratory, Yunnan Provincial Hospital of Infectious Disease, Kunming, Yunnan, China.
Tingting DiaoDepartment of Clinical Laboratory, The Third People's Hospital of Kunming City, Kunming, China.
Cuixian YangMedical Laboratory, Yunnan Provincial Hospital of Infectious Disease, Kunming, Yunnan, China.
Xinlin WuFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China.
Yungui TuThe Affiliated Anning First People's Hospital, Kunming University of Science and Technology, Kunming, China.
Hongji ZhangDepartment of Clinical Laboratory, The Third People's Hospital of Kunming City, Kunming, China.
Chao ZhouFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China.
Pei LeiFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China.
Li Liu *Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China.
Xueshan XiaYunnan Provincial Key Laboratory of Public Health and Biosafety, Kunming Medical University, Kunming, Yunnan, China. oliverxia2000@aliyun.com.
Yue FengFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China. fyky2005@163.com.

Funding

Yunnan Major Scientific and Technological Projects (202202AG050013, 202302AA310044, 202405AJ310002, and 202502AA310025
6 · The paper itself

Abstract

backgroundRapidly detecting drug-resistant Mycobacterium tuberculosis (MTB) is essential for effective tuberculosis (TB) treatment. We have developed a one-tube nested fluorescence melting curve assay (OTN-FMCA) that allows rapid and simultaneous detection of resistance to rifampicin, isoniazid, fluoroquinolones, and bedaquiline.

resultsThe OTN-FMCA uses nested PCR and locked nucleic acid (LNA)-modified probes to identify 44 mutations in six key genes (rpoB, katG, inhA, gyrA, gyrB, and atpE), achieving a detection limit of 5 copies per microliter and identifying up to 10% heterogeneous resistance. When tested on 198 culture-positive isolates, OTN-FMCA demonstrated high concordance with microarray susceptibility testing, with 100% sensitivity and 96.89% specificity. Further validation with 518 sputum samples confirmed its ability to classify patients into different drug resistance categories, including DS-TB, RR-TB, MDR-TB, pre-XDR-TB, and XDR-TB. OTN-FMCA offers a faster, more affordable, and more accessible alternative to current comprehensive drug resistance profiling methods, especially in resource-limited settings.

conclusionsOTN-FMCA is a promising tool for the rapid and accurate detection of drug resistance in MTB, which could improve the management of drug-resistant TB.

Indexed as

Mycobacterium tuberculosisPolymerase Chain ReactionTuberculosis, Multidrug-ResistantAntitubercular AgentsBacterial ProteinsDiarylquinolinesDNA, BacterialDrug Resistance, BacterialDrug Resistance, Multiple, BacterialFluorescenceHumansIsoniazidMicrobial Sensitivity TestsMutationSensitivity and SpecificitySputumAntitubercular AgentsBacterial ProteinsbedaquilineDiarylquinolinesDNA, BacterialIsoniazidDrug resistanceFluorescence melting curve analysisMycobacterium tuberculosisTuberculosis

Identifiers

PMID41420205
PMCPMC12859952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.